Ocumension Therapeutics NMPA accepts dexamethasone intraocular suspension application
Ocumension Therapeutics said its dexamethasone intraocular suspension application was accepted by NMPA.
Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
1 result loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Ocumension Therapeutics said its dexamethasone intraocular suspension application was accepted by NMPA.